---
title: "Pharma Friday roundup: FDA OKs Emcitate for MCT8 deficiency; Lynkuet priority review; Lilly’s Onsw"
id: "endocrine-news-0-pharma-friday-oct-2-2026"
canonical_url: "https://medichelpline.com/clinical-feed/endocrine-news-0-pharma-friday-oct-2-2026"
content_type: "clinical_feed_article"
specialty: "Endocrinology"
source_name: "Endocrine News"
source_url: "https://endocrinenews.endocrine.org/pharma-friday-oct-2-2026/"
published_at: "2026-10-02T16:50:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Pharma Friday roundup: FDA OKs Emcitate for MCT8 deficiency; Lynkuet priority review; Lilly’s Onsw
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/endocrine-news-0-pharma-friday-oct-2-2026
- **Specialty:** [Endocrinology](https://medichelpline.com/clinical-feed/endocrinology.md)
- **Primary Source:** Endocrine News
- **Source URL:** [Original Journal Publication](https://endocrinenews.endocrine.org/pharma-friday-oct-2-2026/)
- **Published At:** 2026-10-02T16:50:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This Pharma Friday summarizes three regulatory updates in endocrinology: FDA approval of **Emcitate (tiratricol)** for MCT8 deficiency, FDA acceptance and Priority Review of Bayer’s **Lynkuet (elinzanetant)** sNDA for vasomotor symptoms related to endocrine therapy for HR+ breast cancer, and FDA approval of Lilly’s once-weekly basal insulin **Onswik (insulin efsitora alfa-gobe)** for adults with type 2 diabetes. - Emcitate received FDA approval on Sept. 28 to treat peripheral thyrotoxicosis in patients with **MCT8 deficiency** (Allan-Herndon-Dudley syndrome). The drug’s active ingredient can enter cells without the defective MCT8 transporter, lowering elevated blood thyroid hormone levels and improving cardiovascular and metabolic symptoms in clinical studies. - The Emcitate approval was supported by two clinical studies including a randomized, placebo-controlled international trial (NCT05579327) and a longer-term open-label study; reported benefits included reductions in circulating thyroid hormone and improvements in systolic blood pressure and heart rate. Common adverse events included diarrhea, vomiting, rash and excessive sweating. Emcitate has multiple expedited designations and the approval was granted to Egetis Therapeutics US Inc. - The FDA accepted Bayer’s supplemental NDA for **Lynkuet (elinzanetant)** on Sept. 28 and granted Priority Review for the indication of moderate to severe vasomotor symptoms (VMS) in women receiving endocrine therapy for HR+ breast cancer. Lynkuet is a dual NK-1/NK-3 receptor antagonist already approved in Oct. 2025 for menopausal VMS. - The sNDA relied on Phase III OASIS-4 data: a 52-week, double-blind, randomized, placebo-controlled trial of 474 women at 90 non-U.S. sites, randomized 2:1 to elinzanetant or placebo then open-label. Lynkuet met primary endpoints reducing mean daily frequency of moderate to severe VMS at weeks 4 and 12 versus placebo. Adverse events included headache, fatigue and somnolence; during the 12-week placebo-controlled period somnolence, fatigue and diarrhea were more frequent with elinzanetant. - The OASIS-4 findings were presented at ASCO 2025 and published in the New England Journal of Medicine. The report notes the clinical need because endocrine therapy for HR+ breast cancer commonly causes hot flashes and that no U.S. FDA-approved treatment for endocrine therapy–related VMS existed at the time of the announcement. - On Sept. 24, Lilly announced FDA approval of **Onswik (insulin efsitora alfa-gobe)**, a once-weekly basal insulin indicated with diet and exercise to control hyperglycemia in adults with type 2 diabetes. Approval was based on QWINT Phase 3 trials in over 3,400 adults showing noninferior A1C reduction versus daily basal insulins. - Onswik demonstrated a safety profile similar to daily basal insulins in trials. It is not for type 1 diabetes because of increased severe hypoglycemia risk. Common side effects include hypoglycemia, allergic reactions, injection-site reactions, lipodystrophy, itching, rash, peripheral swelling and weight gain. KwikPen concentrations and availability details were noted. - The article reiterates broader epidemiologic context: about one in eight Americans have diabetes, most with type 2; global projections to 2030 and the ongoing role of insulin in diabetes management were cited. Inclusion in the roundup does not imply endorsement by Endocrine News or the Endocrine Society.
## Clinical Analysis & Structured Key Points
[Skip to content](https://endocrinenews.endocrine.org/pharma-friday-oct-2-2026/#wp--skip-link--target) [Endocrine News](https://endocrinenews.endocrine.org) [![Endocrine News](https://endocrinenews.endocrine.org/wp-content/uploads/es-reversed.svg)](https://endocrinenews.endocrine.org/) * [Topics](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Diabetes](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Obesity](https://endocrinenews.endocrine.org/category/health-topic/obesity/) * [Adrenal](https://endocrinenews.endocrine.org/category/health-topic/adrenal/) * [Bone and Mineral](https://endocrinenews.endocrine.org/category/health-topic/bone-and-mineral/) * [Cardiometabolic](https://endocrinenews.endocrine.org/category/health-topic/cardiometabolic/) * [Endocrine Disruptors](https://endocrinenews.endocrine.org/category/health-topic/endocrine-disruptors/) * [Head Glands](https://endocrinenews.endocrine.org/category/health-topic/head-glands/) * [Kidney Issues](https://endocrinenews.endocrine.org/category/health-topic/kidney-issues/) * [Neoplasia and Cancer](https://endocrinenews.endocrine.org/category/health-topic/neoplasia-and-cancer/) * [Pancreas](https://endocrinenews.endocrine.org/category/health-topic/pancreas/) * [Reproductive Issues](https://endocrinenews.endocrine.org/category/health-topic/reproductive-issues/) * [Thyroid](https://endocrinenews.endocrine.org/category/health-topic/thyroid/) * [Pediatric Health](https://endocrinenews.endocrine.org/category/patient-populations/pediatric-health/) * [Men’s Health](https://endocrinenews.endocrine.org/category/patient-populations/mens-health/) * [Women’s Health](https://endocrinenews.endocrine.org/category/patient-populations/womens-health/) * [Why Endocrinology?](https://endocrinenews.endocrine.org/category/why-endocrinology/) * [Practice](https://endocrinenews.endocrine.org/category/practice/) * [Your Practice](https://endocrinenews.endocrine.org/category/practice/your-practice/) * [Your Patients](https://endocrinenews.endocrine.org/category/practice/your-patients/) * [Product / Technology](https://endocrinenews.endocrine.org/category/practice/product-technology/) * [Endocrinology Workforce](https://endocrinenews.endocrine.org/category/endocrinology-workforce/) * [Lab Notes](https://endocrinenews.endocrine.org/category/lab-notes/) * [Q&A](https://endocrinenews.endocrine.org/category/lab-notes/q-a/) * [Your Laboratory](https://endocrinenews.endocrine.org/category/your-laboratory/) * [Products and Technological Advancements in Endocrinology](https://endocrinenews.endocrine.org/category/lab-notes/products-technology/) * [Advocacy](https://endocrinenews.endocrine.org/category/advocacy/) * [Clinical](https://endocrinenews.endocrine.org/category/advocacy/clinical/) * [Research](https://endocrinenews.endocrine.org/category/advocacy/research/) * [InTouch](https://endocrinenews.endocrine.org/intouch/) * [Member News](https://endocrinenews.endocrine.org/category/in-touch/member-news-in-touch/) * [Society News](https://endocrinenews.endocrine.org/category/in-touch/society-news/) * [Podcast](https://www.endocrine.org/podcast) * [Current Issue Download](https://endocrinenews.endocrine.org/magazine/current-issue/) * [My Profile](https://ams.endocrine.org/eweb/) * [Log In](https://endocrinenews.endocrine.org/auth/login) * [Log Out](https://endocrinenews.endocrine.org/auth/logout) * [Topics](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Diabetes](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Obesity](https://endocrinenews.endocrine.org/category/health-topic/obesity/) * [Adrenal](https://endocrinenews.endocrine.org/category/health-topic/adrenal/) * [Bone and Mineral](https://endocrinenews.endocrine.org/category/health-topic/bone-and-mineral/) * [Cardiometabolic](https://endocrinenews.endocrine.org/category/health-topic/cardiometabolic/) * [Endocrine Disruptors](https://endocrinenews.endocrine.org/category/health-topic/endocrine-disruptors/) * [Head Glands](https://endocrinenews.endocrine.org/category/health-topic/head-glands/) * [Kidney Issues](https://endocrinenews.endocrine.org/category/health-topic/kidney-issues/) * [Neoplasia and Cancer](https://endocrinenews.endocrine.org/category/health-topic/neoplasia-and-cancer/) * [Pancreas](https://endocrinenews.endocrine.org/category/health-topic/pancreas/) * [Reproductive Issues](https://endocrinenews.endocrine.org/category/health-topic/reproductive-issues/) * [Thyroid](https://endocrinenews.endocrine.org/category/health-topic/thyroid/) * [Pediatric Health](https://endocrinenews.endocrine.org/category/patient-populations/pediatric-health/) * [Men’s Health](https://endocrinenews.endocrine.org/category/patient-populations/mens-health/) * [Women’s Health](https://endocrinenews.endocrine.org/category/patient-populations/womens-health/) * [Why Endocrinology?](https://endocrinenews.endocrine.org/category/why-endocrinology/) * [Practice](https://endocrinenews.endocrine.org/category/practice/) * [Your Practice](https://endocrinenews.endocrine.org/category/practice/your-practice/) * [Your Patients](https://endocrinenews.endocrine.org/category/practice/your-patients/) * [Product / Technology](https://endocrinenews.endocrine.org/category/practice/product-technology/) * [Endocrinology Workforce](https://endocrinenews.endocrine.org/category/endocrinology-workforce/) * [Lab Notes](https://endocrinenews.endocrine.org/category/lab-notes/) * [Q&A](https://endocrinenews.endocrine.org/category/lab-notes/q-a/) * [Your Laboratory](https://endocrinenews.endocrine.org/category/your-laboratory/) * [Products and Technological Advancements in Endocrinology](https://endocrinenews.endocrine.org/category/lab-notes/products-technology/) * [Advocacy](https://endocrinenews.endocrine.org/category/advocacy/) * [Clinical](https://endocrinenews.endocrine.org/category/advocacy/clinical/) * [Research](https://endocrinenews.endocrine.org/category/advocacy/research/) * [InTouch](https://endocrinenews.endocrine.org/intouch/) * [Member News](https://endocrinenews.endocrine.org/category/in-touch/member-news-in-touch/) * [Society News](https://endocrinenews.endocrine.org/category/in-touch/society-news/) * [Podcast](https://www.endocrine.org/podcast) * [Current Issue Download](https://endocrinenews.endocrine.org/magazine/current-issue/) * [My Profile](https://ams.endocrine.org/eweb/) * [Log In](https://endocrinenews.endocrine.org/auth/login) * [Log Out](https://endocrinenews.endocrine.org/auth/logout) Search Search [Current Issue Download](https://endocrinenews.endocrine.org/magazine-issues/september-2026/) [Login](https://endocrinenews.endocrine.org/auth/login/?redirect=https://endocrinenews.endocrine.org/pharma-friday-oct-2-2026/) ![](https://endocrinenews.endocrine.org/wp-content/themes/mg-starter/assets/images/Endocrine_News_standard_logo.svg) * * * # Pharma Friday – Oct. 2, 2026 October 2, 2026 Print this article Share this article #### An _Endocrine News_ roundup of the week’s pharmaceutical news, breakthroughs, and general information. * ## FDA Approves First Treatment for MCT8 Deficiency On Sept. 28, the U.S. Food and Drug Administration (FDA) approved Emcitate (tiratricol) tablets for oral suspension to treat peripheral thyrotoxicosis (excess thyroid hormone levels in the blood that causes symptoms, such as rapid heart rate, increased blood pressure and adverse effects on metabolism) in patients with MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome. Emcitate is the first therapy approved by the FDA to treat symptoms of this very rare, devastating genetic disease. This approval reflects the FDA’s dedication to patients with rare genetic diseases, many of whom have serious unmet medical needs. MCT8 deficiency is a rare genetic disorder that primarily affects males. The condition is caused by a faulty gene that provides instructions for making the MCT8 transporter, a critical protein responsible for carrying thyroid hormone into the brain. Because thyroid hormone cannot cross the blood-brain barrier without the MCT8 transporter, the brain receives too little of this hormone, while excessive levels of the hormone build up in the bloodstream. Many patients with MCT8 deficiency experience a range of debilitating effects, including the inability to walk or sit independently, absent or severely limited speech, intellectual disability, feeding difficulties and chronic stress on the heart and metabolism. “The challenge in treating MCT8 deficiency has always been that the protein needed to deliver thyroid hormone into cells is the one that isn’t working,” said**Endocrine Society member Hylton V. Joffe, MD, MMSc, director of the Office of Cardiology, Hematology, Endocrinology, and Nephrology in the FDA’s Center for Drug Evaluation and Research**. “This drug sidesteps that problem, as its active ingredient, tiratricol, can enter cells on its own without relying on the broken transporter, leading to a decrease in the elevated blood thyroid hormone levels.” The effectiveness of Emcitate was evaluated in two clinical studies in patients ranging in age from infants to adults, including an international, multi-center, randomized, placebo-controlled trial ([NCT05579327](https://clinicaltrials.gov/study/NCT05579327)) and a longer-term open-label study. Across both studies, patients treated with Emcitate had reductions in excess thyroid hormone levels in the bloodstream and improvements in cardiovascular and metabolic symptoms impacted by thyroid levels, such as systolic blood pressure and heart rate. Emcitate is taken once daily as a liquid suspension, either by mouth or through a feeding tube for patients who have difficulty swallowing, making it accessible for patients with a wide range of abilities. The most common side effects were diarrhea, vomiting, rash and excessive sweating. Patients taking another thyroid medication should talk to their healthcare provider before starting Emcitate, as the two should not be used together. Emcitate was granted [Orphan Drug](https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products), [Rare Pediatric Disease](https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/rare-pediatric-disease-designation-and-priority-review-voucher-programs), [Fast Track](https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track) and [Breakthrough Therapy](https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy) designations as well as [Priority Review](https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/priority-review). The approval of Emcitate was granted to Egetis Therapeutics US Inc. ## **FDA Accepts sNDA and Grants Priority Review to Bayer’s Lynkuet ® (elinzanetant) for a New Indication for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Endocrine Therapy Related to Breast Cancer** On Sept. 28, **[Bayer](https://www.bayer.com/en/portfolio/pharmaceuticals)** announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) and granted Priority Review designation for Lynkuet® (elinzanetant) under investigation for the treatment of moderate to severe vasomotor symptoms (VMS, also known as hot flashes) in women receiving endocrine therapy for treatment of breast cancer. First approved by the FDA in October 2025 for the treatment of moderate to severe VMS due to menopause, Lynkuet is a dual neurokinin (NK) targeted therapy, neurokinin 1 (NK-1) and neurokinin 3 (NK-3) receptor antagonist. ![](https://endocrinenews.endocrine.org/wp-content/uploads/Bayer_Logo.jpg) “Currently, there are no FDA approved treatment options for moderate to severe vasomotor symptoms associated with endocrine therapy in patients with HR+ breast cancer in the U.S. This treatment gap underscores an important unmet medical need for this population,” said Kristie Baisden, DO, vice president, U.S. Medical Affairs, Women’s Health at Bayer. “As a global leader in women’s healthcare, this priority review is an important milestone for Bayer and underscores our commitment to women’s health and making treatment options available. We look forward to working closely with the Agency as they review the application.” The sNDA for Lynkuet is based on results of the Phase III OASIS-4 trial. Key details and findings from the study include: * The OASIS-4 study was a 52-week, double-blind, randomized placebo-controlled Phase III interventional study conducted at 90 sites outside of the U.S. A total of 474 women 18 to 70 years of age with moderate to severe VMS associated with endocrine therapy for HR+ breast cancer or its prevention were randomized 2:1 to elinzanetant (n=316) for 52 weeks or placebo for 12 weeks, followed by elinzanetant for 40 weeks (n=158). * Lynkuet met the primary endpoints of reducing the mean daily frequency of moderate to severe VMS symptoms from baseline to week 4 and 12 compared to placebo, in women receiving endocrine therapy for treatment or prevention of HR+ breast cancer. * Common adverse events during the trial were headache, fatigue, and somnolence. During the placebo controlled period of the study for the first 12 weeks, somnolence, fatigue, and diarrhea were reported more frequently with elinzanetant than with placebo. * The key findings were presented at ASCO 2025 and simultaneously published in the _New England Journal of Medicine_ (NEJM) in June 2025. In the U.S., breast cancer accounts for 30% of all cancers in women, with HR+ cancers comprising approximately 70% of all breast cancer cases. HR+ breast cancer treatment guidelines from the American Society of Clinical Oncology recommend endocrine therapy, with a minimum duration of use of five years, with potential extension to 10 years based on cancer type and other clinical considerations. Hot flashes can be a common side effect of endocrine therapy treatment. “Endocrine therapy is a standard of care for many women facing HR+ breast cancer and can commonly cause side effects such as vasomotor symptoms,” said OASIS-4 primary investigator Fatima Cardoso, MD, FESMO director, Breast Unit, Centre Antoine Lacassagne and Advanced Breast Cancer (ABC) Global Alliance, Nice, France. “It’s important that we continue to learn more about vasomotor symptoms due to endocrine therapy as part of supporting women throughout their breast cancer care journey.” The October 2025 FDA approval was supported by data from three Phase III clinical trials (OASIS-1, OASIS-2 and OASIS-3) evaluating the safety and efficacy of Lynkuet for the treatment of moderate to severe hot flashes due to menopause. ## FDA Approves Lilly’s Onswik™ (insulin efsitora alfa-gobe) for Adults Living with Type 2 Diabetes On Sept 24, Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) approval of Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin, indicated along with diet and exercise to control high blood sugar in adults with type 2 diabetes. Onswik is designed to deliver steady basal insulin levels over a full seven days. “For over a century, Lilly has been developing insulins that transformed diabetes care for millions of people worldwide, but delays in initiating treatment and the burden of daily injections can have a real impact on patients’ day-to-day experience managing type 2 diabetes,” said Kenneth Custer, PhD, executive vice president and president, Lilly Cardiometabolic Health. “Onswik offers a new once-weekly basal insulin option for patients and reflects our continued commitment to deliver innovative treatment options that expand choice and provide greater flexibility in how people manage type 2 diabetes.” ![](https://endocrinenews.endocrine.org/wp-content/uploads/eli_lilly_and_company_logo.jpg) This is the fourth global approval for Onswik for adults with type 2 diabetes, following regulatory actions from the European Medicines Agency (EMA), Mexico’s Federal Commission for the Protection against Sanitary Risks (COFEPRIS) and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). The FDA approval is based on data from the QWINT Phase 3 clinical trials, which evaluated the safety and efficacy of once-weekly Onswik in over 3,400 adults with type 2 diabetes. In each QWINT trial, once-weekly Onswik met the primary endpoint of non-inferior A1C reduction from baseline that was comparable to insulin glargine U-100 (glargine) or insulin degludec U-100 (degludec). In these clinical trials, Onswik demonstrated an overall safety profile similar to the daily basal insulins studied. Onswik should not be used by people who have type 1 diabetes due to increased risk of severe hypoglycemia (low blood sugar). Common side effects of Onswik include low blood sugar, allergic reactions, reactions at the injection site, skin thickening or pits at the injection site (lipodystrophy), itching, rash, swelling of hands and feet, and weight gain. Please see **Indication and Safety Summary** below and full [**Prescribing Information**](https://pi.lilly.com/us/onswik-uspi.pdf?s=pi) and [**Patient Information**](https://pi.lilly.com/us/onswik-us-ppi.pdf?s=ppi)**.** Around one in eight Americans live with diabetes, and most of them have type 2 diabetes. Globally by 2030, over 510 million people are expected to live with the disease and 38 million of these are expected to use insulin.8 Insulin remains an important treatment option for many people with type 2 diabetes who do not achieve glycemic goals with other therapies. The Onswik™ KwikPen® will be available in the U.S. in the coming months in two concentrations: 500 units/mL (contains 1,500 units total) and 1,000 units/mL (contains 3,000 units total). For more information about Onswik, please visit [**www.onswik.lilly.com**](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4781735-1&h=2373004481&u=https%3A%2F%2Fwww.onswik.lilly.com%2F&a=www.onswik.lilly.com). ##### *Inclusion in Pharma Fridays does not suggest an endorsement by _Endocrine News_ or the Endocrine Society. * * * ## TOPICS IN THIS ARTICLE: [Pharma Fridays](https://endocrinenews.endocrine.org/category/pharma-fridays/) ←[Reframing Failure: Regaining Momentum After Setbacks in the Lab](https://endocrinenews.endocrine.org/reframing-failure-regaining-momentum-after-setbacks-in-the-lab/) ## RELATED ARTICLES * ### [ Eureka! The Top Endocrine Discoveries of 2024 – Part V ](https://endocrinenews.endocrine.org/eureka-the-top-endocrine-discoveries-of-2024-part-v/) December 30, 2024 * ### [ Eureka! The Top Endocrine Science of 2024 – Part IV ](https://endocrinenews.endocrine.org/eureka-the-top-endocrine-science-of-2024-part-iv/) December 26, 2024 * ### [ Eureka! The Top Endocrine Science of 2024 – Part III ](https://endocrinenews.endocrine.org/eureka-the-top-endocrine-science-of-2024-part-iii/) December 23, 2024 * * * ADVERTISEMENT ![September 2026](https://endocrinenews.endocrine.org/wp-content/uploads/09.26.cover_-765x1024.jpg) [View Archives](https://endocrinenews.endocrine.org/magazine-issues/) ADVERTISEMENT ADVERTISEMENT ![](https://endocrinenews.endocrine.org/wp-content/themes/mg-starter/assets/images/scientists_optim-1024x569.jpg) ## Join the Global Movement Advancing Endocrine Science and Medicine Become a part of a community of 18,000-plus endocrine investigators and clinicians who conduct research and provide quality patient care in more than 100 countries. Advance your career and the field of endocrinology through our many educational, leade
## Related Clinical Research

- [Key Developments in Endocrinology for October 16, 2026](https://medichelpline.com/clinical-feed/endocrine-news-0-pharma-friday-october-16-2026.md)
- [Higher moderate-to-vigorous physical activity linked to lower type 2 diabetes risk](https://medichelpline.com/clinical-feed/medical-news-today-0-more-moderate-to-vigorous-physical-activity-could-reduce-type-2-diabetes-risk.md)
- [GLP-1 receptor agonists and PMOS: evidence, mechanisms, and who may benefit](https://medichelpline.com/clinical-feed/medical-news-today-0-can-glp-1s-really-help-treat-pmos-experts-answer-3-key-questions.md)
- [Undiagnosed type 2 diabetes presenting as DKA with hypertriglyceridemia-induced acute pancreatitis](https://medichelpline.com/clinical-feed/cmaj-1-undiagnosed-type-2-diabetes-presenting-as-diabetic-ketoacidosis-with.md)
- [Insulet and Calm Partner to Offer Mindfulness Tools for People Living with Diabetes](https://medichelpline.com/clinical-feed/endocrine-news-0-pharma-friday-july-17-2026.md)

## Navigation
- [← Back to Endocrinology Feed](https://medichelpline.com/clinical-feed/endocrinology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.